JOHNSON & JOHNSON - 8-K Filing

Johnson & Johnson reports Q3 2026 results with $25.4B in sales, raises full-year guidance due to strong operational performance (Items: 2.02 Results of operations and financial conditionOn October 13, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibi, 9.01 Financial statements and exhibits(d) Exhibits)

SEC EDGAR · October 13, 2026, 12:14 UTC

Tickers: $JNJ

Read the full article at SEC EDGAR

Part of the story JOHNSON & JOHNSON - 8-K Filing (37 articles)

More Regulatory news

Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC
Corteva, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:34 UTC